If LRRK2 kinase activity is indeed elevated in idiopathic PD patients, it would suggest that LRRK2 is driving some aspect of PD pathogenesis and that LRRK2 inhibitors may be efficacious even in patients that do not carry mutations. Here, LRRK2 is linked to Parkinson disease.